# Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

> **NCT02940639** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 499 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02940639
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-27
- **Primary completion:** 2025-06-03
- **Final completion:** 2025-06-03
- **Target enrollment:** 499 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940639, "Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02940639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*